It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve solutions for administration
If a patient is interested in BPC-157, the discussion should include why they are interested, what condition they are trying to address, what has already been diagnosed, what other treatments have been tried, what medications they take, and what safety questions apply
BPC-157 & TB-500: Synergistic peptides for injury recovery The combination of BPC-157 and TB-500 represents a fascinating area of peptide research
Do not blow on the stoppers to speed drying
Peptide Vials (Retatrutide, 10 mg each): 12 weeks (Standard to 6 mg): 5 vials 24 weeks (Standard to 8 mg): 15 vials 12 weeks (Aggressive to 8 mg): 6 vials Insulin Syringes (U-100, 1 mL capacity): Per week: 12 syringes (depending on dose